Abstract | PURPOSE: Due to a lack of early diagnostic markers, pancreatic cancer (PC) remains a lethal disease. Proteomic approaches are now being applied to identify novel PC biomarkers. EXPERIMENTAL DESIGN: In this study, iTRAQ and LC-MS/MS are used to perform comparative analyses of serum from PC patients and healthy controls (HC), to identify specific serum biomarkers for PC. Serum levels of candidate proteins are determined using ELISA. RESULTS: CONCLUSIONS AND CLINICAL RELEVANCE: It is demonstrated that PROZ and TNFRSF6B are novel serum biomarkers for detecting early stage PC, and for distinguishing PC from pancreatic benign tumor and healthy individuals. Additional large cohort studies are needed to develop PROZ and TNFRSF6B as clinical PC biomarkers.
|
Authors | Xing Wu, Zi-Xiang Zhang, Xing-Yu Chen, Ya-Ling Xu, Ni Yin, Jian Yang, Dong-Ming Zhu, De-Chun Li, Jian Zhou |
Journal | Proteomics. Clinical applications
(Proteomics Clin Appl)
Vol. 13
Issue 5
Pg. e1800195
(09 2019)
ISSN: 1862-8354 [Electronic] Germany |
PMID | 31025496
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Chemical References |
|
Topics |
- Adult
- Aged
- Biomarkers, Tumor
(metabolism)
- Early Detection of Cancer
- Female
- Gene Ontology
- Humans
- Male
- Middle Aged
- Pancreatic Neoplasms
(diagnosis, metabolism)
- Proteomics
- Tandem Mass Spectrometry
- Young Adult
|